Molecular advances in medullary thyroid cancer diagnostics

Clinica Chimica Acta

Volumn 370, Issue 1-2, 2006, Pages 2-8

  Hubner, Richard A ^a   Houlston, Richard S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Medullary thyroid cancer; MEN2; RET proto oncogene; Tyrosine kinase

Indexed keywords

PROTEIN RET;

CANCER DIAGNOSIS; CANCER RISK; GENE FUNCTION; GENE MUTATION; GENE REARRANGEMENT; GENE STRUCTURE; GENETIC ANALYSIS; GENETIC RISK; GENOTYPE; HUMAN; MOLECULAR BIOLOGY; MORBIDITY; MULTIPLE ENDOCRINE NEOPLASIA; MUTATIONAL ANALYSIS; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTO ONCOGENE; REVIEW; SIGNAL TRANSDUCTION; THYROID MEDULLARY CARCINOMA;

ANIMALS; CARCINOMA, MEDULLARY; HUMANS; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; MUTATION; PROTO-ONCOGENE PROTEINS C-RET; THYROID NEOPLASMS;

EID: 33746264000     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2006.01.029     Document Type: Review

References (58)

1. Hazard J.B., Hawk W.A., and Crile Jr. G. Medullary (solid) carcinoma of the thyroid; a clinicopathologic entity. J Clin Endocrinol Metab 19 (1959) 152-161
2. Jemal A., Murray T., Ward E., et al. Cancer statistics, 2005. CA Cancer J Clin 55 (2005) 10-30
3. DeVita V., Hellman S., and Rosenberg S. Principles and practice of oncology. seventh ed. (2005), Lippincott Williams and Wilkinson, Philadelphia
4. Brandi M.L., Gagel R.F., Angeli A., et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86 (2001) 5658-5671
5. Mulligan L.M., Kwok J.B., Healey C.S., et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363 (1993) 458-460
6. Donis-Keller H., Dou S., Chi D., et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 2 (1993) 851-856
7. Eng C., and Mulligan L.M. Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and hirschsprung disease. Hum Mutat 9 (1997) 97-109
8. Machens A., Niccoli-Sire P., Hoegel J., et al. Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 349 (2003) 1517-1525
9. Yip L., Cote G.J., Shapiro S.E., et al. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Arch Surg 138 (2003) 409-416
10. Larsen P., Kronenberg H., Melmed S., and Polonsky K. Multiple endocrine neoplasia. tenth ed. (2003), Saunders, Philadelphia
11. Eng C. RET proto-oncogene in the development of human cancer. J Clin Oncol 17 (1999) 380-393
12. Jimenez C., and Gagel R.F. Genetic testing in endocrinology: lessons learned from experience with multiple endocrine neoplasia type 2 (MEN2). Growth Horm IGF Res 14 Suppl A (2004) S150-S157
13. Kouvaraki M.A., Shapiro S.E., Perrier N.D., et al. RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 15 (2005) 531-544
14. Cotran R.S., Kumar V., and Collins T. Robbins pathologic basis of disease. sixth ed. (1999), Saunders, Philadelphia
15. Leboulleux S., Baudin E., Travagli J.P., and Schlumberger M. Medullary thyroid carcinoma. Clin Endocrinol (Oxf) 61 (2004) 299-310
16. Kaufman F.R., Roe T.F., Isaacs Jr. H., and Weitzman J.J. Metastatic medullary thyroid carcinoma in young children with mucosal neuroma syndrome. Pediatrics 70 (1982) 263-267
17. Carlomagno F., Vitagliano D., Guida T., et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 62 (2002) 7284-7290
18. Takahashi M., Ritz J., and Cooper G.M. Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell 42 (1985) 581-588
19. Takahashi M., Buma Y., Iwamoto T., Inaguma Y., Ikeda H., and Hiai H. Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains. Oncogene 3 (1988) 571-578
20. Pachnis V., Mankoo B., and Costantini F. Expression of the c-ret proto-oncogene during mouse embryogenesis. Development 119 (1993) 1005-1017
21. Schuchardt A., D'Agati V., Larsson-Blomberg L., Costantini F., and Pachnis V. Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret. Nature 367 (1994) 380-383
22. Taraviras S., Marcos-Gutierrez C.V., Durbec P., et al. Signalling by the RET receptor tyrosine kinase and its role in the development of the mammalian enteric nervous system. Development 126 (1999) 2785-2797
23. Enomoto H., Crawford P.A., Gorodinsky A., Heuckeroth R.O., Johnson Jr. E.M., and Milbrandt J. RET signaling is essential for migration, axonal growth and axon guidance of developing sympathetic neurons. Development 128 (2001) 3963-3974
24. Tahira T., Ishizaka Y., Itoh F., Sugimura T., and Nagao M. Characterization of ret proto-oncogene mRNAs encoding two isoforms of the protein product in a human neuroblastoma cell line. Oncogene 5 (1990) 97-102
25. Myers S.M., Eng C., Ponder B.A., and Mulligan L.M. Characterization of RET proto-oncogene 3′ splicing variants and polyadenylation sites: a novel C-terminus for RET. Oncogene 11 (1995) 2039-2045
26. de Graaff E., Srinivas S., Kilkenny C., et al. Differential activities of the RET tyrosine kinase receptor isoforms during mammalian embryogenesis. Genes Dev 15 (2001) 2433-2444
27. Lee D.C., Chan K.W., and Chan S.Y. RET receptor tyrosine kinase isoforms in kidney function and disease. Oncogene 21 (2002) 5582-5592
28. Tsui-Pierchala B.A., Ahrens R.C., Crowder R.J., Milbrandt J., and Johnson Jr. E.M. The long and short isoforms of Ret function as independent signaling complexes. J Biol Chem 277 (2002) 34618-34625
29. Lin L.F., Doherty D.H., Lile J.D., Bektesh S., and Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260 (1993) 1130-1132
30. Kotzbauer P.T., Lampe P.A., Heuckeroth R.O., et al. Neurturin, a relative of glial-cell-line-derived neurotrophic factor. Nature 384 (1996) 467-470
31. Milbrandt J., de Sauvage F.J., Fahrner T.J., et al. Persephin, a novel neurotrophic factor related to GDNF and neurturin. Neuron 20 (1998) 245-253
32. Baloh R.H., Tansey M.G., Lampe P.A., et al. Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRalpha3-RET receptor complex. Neuron 21 (1998) 1291-1302
33. Airaksinen M.S., and Saarma M. The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci 3 (2002) 383-394
34. Hayashi H., Ichihara M., Iwashita T., et al. Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell line-derived neurotrophic factor. Oncogene 19 (2000) 4469-4475
35. Akhand A.A., Ikeyama T., Akazawa S., et al. Evidence of both extra- and intracellular cysteine targets of protein modification for activation of RET kinase. Biochem Biophys Res Commun 292 (2002) 826-831
36. Hofstra R.M., Landsvater R.M., Ceccherini I., et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 367 (1994) 375-376
37. Eng C., Smith D.P., Mulligan L.M., et al. A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene 10 (1995) 509-513
38. Asai N., Iwashita T., Matsuyama M., and Takahashi M. Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol Cell Biol 15 (1995) 1613-1619
39. Santoro M., Carlomagno F., Romano A., et al. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 267 (1995) 381-383
40. Kodama Y., Asai N., Kawai K., et al. The RET proto-oncogene: a molecular therapeutic target in thyroid cancer. Cancer Sci 96 (2005) 143-148
41. Iwashita T., Asai N., Murakami H., Matsuyama M., and Takahashi M. Identification of tyrosine residues that are essential for transforming activity of the ret proto-oncogene with MEN2A or MEN2B mutation. Oncogene 12 (1996) 481-487
42. Salassidis K., Bruch J., Zitzelsberger H., Lengfelder E., Kellerer A.M., and Bauchinger M. Translocation t(10;14)(q11.2:q22.1) fusing the kinetin to the RET gene creates a novel rearranged form (PTC8) of the RET proto-oncogene in radiation-induced childhood papillary thyroid carcinoma. Cancer Res 60 (2000) 2786-2789
43. Klugbauer S., Jauch A., Lengfelder E., Demidchik E., and Rabes H.M. A novel type of RET rearrangement (PTC8) in childhood papillary thyroid carcinomas and characterization of the involved gene (RFG8). Cancer Res 60 (2000) 7028-7032
44. Eng C., Clayton D., Schuffenecker I., et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 276 (1996) 1575-1579
45. Mulligan L.M., Marsh D.J., Robinson B.G., et al. Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. J Intern Med 238 (1995) 343-346
46. Mulligan L.M., Eng C., Healey C.S., et al. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet 6 (1994) 70-74
47. Jimenez C., Dang G.T., Schultz P.N., et al. A novel point mutation of the RET protooncogene involving the second intracellular tyrosine kinase domain in a family with medullary thyroid carcinoma. J Clin Endocrinol Metab 89 (2004) 3521-3526
48. Bolino A., Schuffenecker I., Luo Y., et al. RET mutations in exons 13 and 14 of FMTC patients. Oncogene 10 (1995) 2415-2419
49. Ichihara M., Murakumo Y., and Takahashi M. RET and neuroendocrine tumors. Cancer Lett 204 (2004) 197-211
50. Bocciardi R., Mograbi B., Pasini B., et al. The multiple endocrine neoplasia type 2B point mutation switches the specificity of the Ret tyrosine kinase towards cellular substrates that are susceptible to interact with Crk and Nck. Oncogene 15 (1997) 2257-2265
51. Murakami H., Iwashita T., Asai N., et al. Enhanced phosphatidylinositol 3-kinase activity and high phosphorylation state of its downstream signalling molecules mediated by ret with the MEN 2B mutation. Biochem Biophys Res Commun 262 (1999) 68-75
52. Murakami H., Yamamura Y., Shimono Y., Kawai K., Kurokawa K., and Takahashi M. Role of Dok1 in cell signaling mediated by RET tyrosine kinase. J Biol Chem 277 (2002) 32781-32790
53. Marshall G.M., Peaston A.E., Hocker J.E., et al. Expression of multiple endocrine neoplasia 2B RET in neuroblastoma cells alters cell adhesion in vitro, enhances metastatic behavior in vivo, and activates Jun kinase. Cancer Res 57 (1997) 5399-5405
54. Ito S., Iwashita T., Asai N., et al. Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype. Cancer Res 57 (1997) 2870-2872
55. Carlomagno F., Salvatore G., Cirafici A.M., et al. The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype. Cancer Res 57 (1997) 391-395
56. Eng C., Mulligan L.M., Smith D.P., et al. Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma. Clin Endocrinol 43 (1995) 123-127
57. Wohllk N., Cote G.J., Bugalho M.M., et al. Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 81 (1996) 3740-3745
58. Moore F.D., and Dluhy R.G. Prophylactic thyroidectomy in MEN-2A-a stitch in time?. N Engl J Med 353 (2005) 1162-1164